Elanco Animal Health Incorporated is a premier global animal health company dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The company's business is broadly divided into two main segments: Pet Health and Farm Animal, each contributing roughly half of total revenue. The Pet Health portfolio focuses on parasiticides, vaccines, and therapeutics, featuring blockbuster products like Credelio, AdTab, and Zenrelia that protect pets from fleas, ticks, internal parasites, and manage chronic conditions such as osteoarthritis and dermatitis. The Farm Animal segment provides disease prevention products, antibiotics, implants, vaccines, and functional nutritional health products (including enzymes, probiotics, and prebiotics) for the beef, dairy, poultry, and swine industries. A key growth driver in this segment is Experior, a feed additive that reduces ammonia gas emissions. Elanco sells its products to third-party distributors, veterinarians, and food animal producers across more than 90 countries. Originally established in 1954 as a division of Eli Lilly and Company, Elanco was spun off as an independent public company in 2018. The company maintains a strong competitive position as one of the largest animal health businesses globally, leveraging a robust pipeline of innovative veterinary pharmaceuticals to drive long-term growth.
